David Fairman (Dave Fairman)

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 7

Top Topics

Placebo Controlled

Top Venues

Pharmacology research & perspectives

CPT: pharmacometrics & systems pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Jan Berkhout, David Fairman, Martijn van Noort, Tamara J van Steeg
A model-based approach using GSK3772847, an anti-interleukin-33 receptor monoclonal antibody, as a showcase to predict SC administration PK and free target dynamics based on PK and total target measurements after IV administration. CPT: pharmacometrics & systems pharmacology (2024)
Eleni Pefani, Sally Stone, Chang-Qing Zhu, Carol Nunn, David Fairman
Safety, tolerability, and pharmacokinetics of a single ascending subcutaneous dose of GSK3772847 in healthy participants. Pharmacology research & perspectives 11 (2) (2023)
Eleni Pefani, Sally Stone, Chang-Qing Zhu, Carol Nunn, David Fairman
Safety, tolerability, and pharmacokinetics of a single ascending subcutaneous dose of GSK3772847 in healthy participants. Pharmacology research & perspectives 11 (2) (2023)
Chika Akinseye, Courtney Crim, Amy Newlands, David Fairman
Efficacy and safety of GSK3772847 in participants with moderate-to-severe asthma with allergic fungal airway disease: A phase IIa randomized, multicenter, double-blind, sponsor-open, comparative trial. PloS one 18 (2) (2023)
Chika Akinseye, Courtney Crim, Amy Newlands, David Fairman
Efficacy and safety of GSK3772847 in participants with moderate-to-severe asthma with allergic fungal airway disease: A phase IIa randomized, multicenter, double-blind, sponsor-open, comparative trial. PloS one 18 (2) (2023)
Chika Akinseye, Courtney Crim, Amy Newlands, David Fairman
Efficacy and safety of GSK3772847 in participants with moderate-to-severe asthma with allergic fungal airway disease: A phase IIa randomized, multicenter, double-blind, sponsor-open, comparative trial. PloS one 18 (2) (2023)
Chika Akinseye, Courtney Crim, Amy Newlands, David Fairman
Efficacy and safety of GSK3772847 in participants with moderate-to-severe asthma with allergic fungal airway disease: A phase IIa randomized, multicenter, double-blind, sponsor-open, comparative trial. PloS one 18 (2) (2023)